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OBJECTIVE
We evaluated whether the increasing number of genetic loci for coronary artery
disease (CAD) identified in the general population could be used to predict the risk
of major CAD events (MCE) among participants with type 2 diabetes at high car-
diovascular risk.
RESEARCH DESIGN AND METHODS
A weighted genetic risk score (GRS) derived from 204 variants representative of all
the 160 CAD loci identified in the general population as of December 2017 was
calculated in 5,360 and 1,931 white participants in the Action to Control Cardio-
vascular Risk in Diabetes (ACCORD) and Outcome Reduction With Initial Glargine
Intervention (ORIGIN) studies, respectively. The association between GRS andMCE
(combining fatal CAD events, nonfatal myocardial infarction, and unstable angina)
was assessed by Cox proportional hazards regression.
RESULTS
The GRS was associated with MCE risk in both ACCORD and ORIGIN (hazard ratio [HR]
per SD 1.27, 95% CI 1.18–1.37, P = 4 3 10210, and HR per SD 1.35, 95% CI 1.16–1.58,
P = 2 3 1024, respectively). This association was independent from interventions
tested in the trials and persisted, though attenuated, after adjustment for classic
cardiovascular risk predictors. Adding the GRS to clinical predictors improved in-
cident MCE risk classification (relative integrated discrimination improvement +8%,
P = 7 3 1024). The performance of this GRS was superior to that of GRS based on
the smaller number of CAD loci available in previous years.
CONCLUSIONS
When combined into a GRS, CAD loci identified in the general population are
associated with CAD also in type 2 diabetes. This GRS provides a significant im-
provement in the ability to correctly predict future MCE, which may increase fur-
ther with the discovery of new CAD loci.
The risk of coronary artery disease (CAD) is between two and five times higher in
patients with type 2 diabetes than in the general population, making CAD the most
common long-term complication of type 2 diabetes (1,2). Given the millions of peo-
ple affected by diabetes in the U.S. and worldwide, the great burden of increased
morbidity and mortality associated with CAD as well as the costs, financial and
otherwise, of preventive programs (3,4), there is a crucial need for new predictive
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tools to identify patients with diabetes
who are at especially high risk for this
complication so that intensive preven-
tion strategies can be targeted at them.
Several clinical characteristics such as
age, male sex, hypertension, dyslipide-
mia, and smoking are known risk factors
for CAD in subjects both with and without
diabetes (5–7). Genetic factors are also
known to contribute to CAD, and 160
different loci associated with increased
CAD risk have been identified to date in
the general population through large
genome-wide association studies (GWAS)
involving hundreds of thousands of in-
dividuals (8–18). Whether these loci are
associated with CAD and/or predict in-
cident major CAD events (MCE) in people
who are, on average, at high cardiovas-
cular risk, such as patients with diabetes,
is unknown at this time. Also unclear is
whether these genetic variants may have
clinical utility in identifying individuals
with diabetes at especially high MCE
risk who may benefit from special pre-
ventive interventions. A previous report
suggested minimal improvements in CAD
prediction by the addition of five CAD-
associated single nucleotide polymor-
phisms (SNPs) to a clinical prediction
model (19), but whether the outcome
may be different with the current larger
pool of CAD loci deserves investigation,
especially in consideration of the pos-
sible interactions between the diabetic
milieu and genetic variants on CAD risk
(20,21).
In this study, we examined the asso-
ciation between the currently available
genetic markers and CAD in people with
type 2 diabetes. We also evaluated the
extent to which these genetic markers
improve the prediction of incident MCE
when added to conventional cardiovas-
cular risk factors and assessed whether
a genetic risk score (GRS) derived from
these SNPs could identify subsets of
patients with type 2 diabetes with dif-
ferent responses to intensive glucose,
blood pressure, and lipid control in the
Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial.
RESEARCH DESIGN AND METHODS
Study Subjects
The ACCORD trial was aimed at eval-
uating whether intensive treatments
targeting hyperglycemia, elevated blood
pressure, and dyslipidemia could reduce
the risk of major adverse cardiovascular
events among patients with high-risk
type 2 diabetes (22). A total of 10,251
participants with type 2 diabetes were
recruited from seven clinical networks in
the U.S. and Canada between 2001 and
2005 and randomized in a 1:1 ratio to re-
ceive intensive glucose-lowering treat-
ment, aiming for an HbA1c level below
6%, or to standard treatment, aiming for
an HbA1c level between 7.0% and 7.9%.
Half of the participants were addition-
ally randomized to a subtrial of intensive
versus standard antihypertensive ther-
apy (ACCORD-BP) (23) and the other half
to a subtrial of fenofibrate + simvastatin
versus simvastatin alone (ACCORD-Lipid)
(24). All study participants provided writ-
ten informed consent according to local
regulations. The present cohort study
was limited to 5,360 self-reported white
participants who provided consent to
genetic studies.
The Outcome Reduction With Initial
Glargine Intervention (ORIGIN) trial (25),
conducted worldwide between 2003 and
2011, investigated the effect of titrated
basal insulin versus standard care and
of n-3 fatty acid supplements versus
placebo on major cardiovascular events
occurrence among 12,537 participants
with impaired fasting glucose, impaired
glucose tolerance or type 2 diabetes, and
high cardiovascular risk. After a median
follow-up time of 6.2 years, the study
reported lack of significant cardiovas-
cular effect of these two treatments.
The current study was limited to 1,931
self-reported white participants who
provided consent for genetic studies.
Outcomes
Baseline history of CAD was defined as
the presence of positive history for
myocardial infarction, coronary revas-
cularization procedures, angina, and/or
documented ischemic changes on a
graded exercise tolerance test or cardiac
imaging. Incident MCEdone of the pre-
specified secondary outcomes of the
ACCORD trial (22)dwere defined as
fatal CAD events, nonfatal myocardial
infarction, or unstable angina occurring
during the trial. In the ORIGIN trial, MCE
were also defined as fatal and nonfatal
myocardial infarction or unstable angina
occurring during the study.
Genotyping and Quality Control
Two-hundred and four independent
SNPs were selected for their genome-
wide significant association with CAD in
GWAS and exome-wide association stud-
ies published as of December 2017, rep-
resenting 160 known CAD loci (8–18)
(Supplementary Table 1). The ADTRP-
C6orf105 locus was not included in the
analysis since it was detected only in Han
Chinese (26) and did not harbor variants
associated with CAD at GWAS significant
levels in any of the more recent studies
(8–18). When multiple SNPs had been
reported to be associated with CAD at a
given locus (defined as a 1-Mb window
on either side), the SNP with the highest
significant association with CAD reported
in literature (sentinel SNP) was selected
first, followed by any other SNP at that
locus (independent SNP) that was not in
linkage disequilibrium (R2 , 0.2) with
the sentinel SNP. Linkage disequilib-
rium between SNPs was assessed with
the LDlink tool (https://analysistools.nci
.nih.gov/LDlink/?tab=home) based on
genotyped data originating from phase
3 (version 5) of the 1000 Genomes Project
among subjects with European ancestry.
Since these CAD loci were discovered
in populations in which the majority of
participants were of European ancestry
(8–18), the current study was limited to
self-reported white participants with ge-
netic data.
For ACCORD, genotypes for the 204
SNPs were derived from the study’s
GWAS data set, the generation of which
has been described in detail elsewhere
(27). Sixty-seven of the 204 SNPs con-
sidered in the study were genotyped
and the remaining 137 imputed at high
quality (median info score 0.98, inter-
quartile range 0.95–0.99). For ORIGIN,
genotypes were derived from a GWAS
data set generated by means of the
HumanCoreExome BeadChip 12 v1.0 and
v1.1 (Illumina), which evaluated 551,839
markers and allowed the imputation of
30 million SNPs using Impute v2.3.1.
Sixty-four of the 204 SNPs were geno-
typed and 138 were imputed at high
quality (median info score 0.96, inter-
quartile range 0.88–0.99). Two of the
204 SNPs (rs112470402 and rs507666)




The association between each SNP and
history of CAD was tested in ACCORD by
logistic regression using an additive ge-
netic model adjusted for age, sex, clinical
network, and principal components of
population structure. To account for
multiple comparisons, study-wide signif-
icance was defined according to a false
discovery rate ,0.05. Post hoc power
calculations (Quanto v1.2.4) showed that
depending on the effect allele frequency,
single SNP analyses were powered (1 –
b = 80%) to detect a study-wide signif-
icant association (a = 2 3 1024) with
history of CAD with an odds ratio [OR]
$1.21, $1.36, and $2.48 for SNPs with
effect allele frequency of 50%, 10%, and
1%, respectively. The corresponding fig-
ures to detect effects at the nominal
significance level (a = 0.05) were OR
$1.13, $1.22, and $1.76. The number
of SNPs showing the same effect direc-
tion as that reported in the literature
was computed and compared with the
binomial distribution of the effect direc-
tions expected on the basis of 204 trials
conducted under the null hypothesis of
equal chances of the effect going in either
direction.
GRS Analysis
A weighted GRS was derived from the
genotypes by adding the numbers of risk
alleles at each variant after weighing them
for the effect magnitudes reported for
each variant in the literature. In ACCORD
a 204-SNP–derived GRS was used, while
in ORIGIN a 202-SNP–derived GRS was
used (since 2 SNPs were not available in
ORIGIN genetic data set). To aid interpre-
tation of the GRS, the GRS were stan-
dardized to a mean of 0 and an SD of 1.
The association of the GRS with history
of CAD was tested by logistic regression
analysis adjusting for age, sex, clinical
network, and principal components of
population structure. The association be-
tween GRS and MCE during follow-up
was evaluated by means of Cox propor-
tional hazards regression. Four different
regression models of increasing complex-
ity were tested: model 1 including GRS,
age, sex, and ACCORD study covariates
(assignment to randomized treatment
arms, clinical network, genotyping plat-
form, and principal components of pop-
ulation structure); model 2 with further
adjustment for history of CAD at base-
line; model 3 with further adjustment for
the 10-year American College of Cardi-
ology (ACC)/American Heart Association
(AHA) atherosclerotic cardiovascular dis-
ease (ASCVD) risk estimator (6) (which
includes total and HDL cholesterol,
smoking habits, systolic blood pressure,
hypertension treatment, and history of
diabetes); model 4 with further adjust-
ments for duration of diabetes, HbA1c
levels at baseline, and family history of
cardiovascular disease. The assumption
of proportionality of the hazards was
formally tested by testing the signifi-
cance of time 3 predictor interaction
terms added to the models. The assump-
tion was respected in all cases.
Kaplan-Meier curves were generated
to illustrate the association between GRS
tertile and incidence of MCE. Influences
of clinical characteristics at baseline (age,
sex, history of CAD, family history of
CAD, median duration of diabetes and
of HbA1c levels at baseline) or of differ-
ent treatments during the trial on the
relationship between GRS and incident
MCE were tested by means of Cox pro-
portional hazards models including the
clinical characteristic or intervention,
the GRS, and a “GRS 3 clinical charac-
teristic/intervention” interaction term.
Power calculations showed that the
GRS was sufficiently powered (1 – b =
80%) to detect a significant association
(a = 0.05)with incidentMCEwith a hazard
ratio (HR) per SD increment as small as
1.13. Analyses of “GRS 3 treatment”
interaction had 80% power (a = 0.05)
to detect coefficients of interaction with
glycemic, blood pressure, and fibrate in-
terventions $0.24, $0.36, and $0.32,
respectively (which would be in the range
of “gene 3 treatment” interactions
estimates detected in previous study,
e.g., 0.27 for gene3 glycemic interven-
tion on nonfatal myocardial infarction or
0.33 for gene 3 fenofibrate interaction
on major cardiovascular events [27,28]).
Replication in ORIGIN Study
Validation of the association between
GRS and MCE was sought by means of
Cox proportional hazards regression
in the ORIGIN study. The same models
tested in ACCORD were evaluated in
ORIGIN: model 1, including GRS, age,
sex, and ORIGIN study covariates (as-
signment to randomized treatment arms
and principal components of population
structure); model 2, with further adjust-
ment for history of CAD at baseline; and
model 3, with further adjustment for the
10-year ACC/AHA ASCVD risk estimator.
Model 4 was not tested since information
on family history of cardiovascular dis-
ease was not available in ORIGIN. Power
analyses showed that the GRS was pow-
ered (1 – b = 80%) to detect a significant
association (a = 0.05) with incident MCE
event with an HR per SD increment as
small as 1.26.
Model Performance for Predicting Risk of
Incident MCE
Model performance in terms of MCE
prediction was compared in ACCORD
across three models: model 1, a genetic
model including the GRS alone; model
2, a clinical model based on conventional
clinical predictors of CAD and including
history of CAD, age, sex, the ACC/AHA
ASCVD risk estimator, and the ACCORD
study covariates; and model 3, a clinical +
genetic model in which the GRS was
added to the clinical model. Receiver
operating characteristic (ROC) curves,
plotting sensitivity against 1 – specificity,
were constructed for all possible cutoffs
for the three models. The area under
the ROC curve (AUC), or C-statistic, was
estimated as a measure of the probability
that a randomly selected individual who
experienced an event had a higher pre-
dicted risk than an event-free person. As
alternative measures of risk discrimi-
nation, we also calculated the relative
integrated discrimination improvement
(rIDI) (29), which represents the increase
in discrimination slopes provided by the
new model relative to the old model, and
the category-free net reclassification in-
dex (NRI) (29), which examines whether
the predicted probabilities of individuals
with and without events move in the
right directions (upward and downward,
respectively) from the old to the new
model. The analyses testing the improve-
ment in predictive performance were
computed using logistic regressionmodels
with methods developed by Kennedy and
Pencina (30).
All the analyses were performed using
the SAS software (version 9.4, SAS In-
stitute Inc., Cary, NC), and all the tests
were two-sided. Graphs were edited
with GraphPad Prism version 7.2.
RESULTS
Genetic Associations With Baseline
Characteristics and Prevalent CAD
Baseline characteristics of the ACCORD
participants included in this study are
shown in Table 1. The distribution of the
GRS (weighted and rescaled to a range
from 0 to 408) showed that participants
carried an average of 187.4 6 8.1 risk
alleles. GRS distributions were similar in
the two glycemic treatment arms (P =
0.63). A higher GRS was associated with
younger age, lower levels of plasma HDL
cholesterol, and higher glomerular filtra-
tion rate (this difference was not signif-
icant after adjustment for age, P = 0.2).
The GRS was also strongly associated
with a positive family history of cardio-
vascular disease and a positive CAD his-
tory at study entry. Specifically, each GRS
SD increment was associated with a 40%
increase in the odds of a positive CAD
history (OR 1.40, 95%CI 1.32–1.49, P = 33
10227), with participants with a GRS in
the third and second tertile having 101%
(OR 2.01, 95% CI 1.73–2.37) and 35% (95%
CI 1.16–1.57) higher odds of CAD, re-
spectively, as compared with partici-
pants with GRS in the lowest tertile
(Supplementary Fig. 1). In individual loci
analysis, 32 SNPs were nominally asso-
ciated with CAD, although none of them
reached study-wide significance (Supple-
mentary Table 2). Overall, 74% of the
SNPs included in the study (151/204,
P value for deviation from 50% =
2 3 10212) showed a trend for an asso-
ciation with prevalent CAD that went in
the same direction as in the general
population.
GRS and Risk of Incident
Coronary Events
A total of 675 participants enrolled in the
ACCORD study suffered one or more MCE
over a median follow-up of 4.7 years. The
GRS was significantly associated with the
risk of experiencing one of these MCE
(HR per SD increment 1.27, 95% CI 1.18–
1.37,P=4310210).As reported in Table
2 (and illustrated graphically by means
of Kaplan-Meier curves in Fig. 1), par-
ticipants with a GRS in the third tertile of
the distribution had a 76% higher risk of
experiencing an MCE event as compared
with those having a GRS in the lowest
tertile (HR 1.76, 95% CI 1.45–2.14). This
association was attenuated, but still sig-
nificant, after further adjustments for
clinical predictors (Table 2). Similar results
were also obtained when alternative
cardiovascular outcomes of ACCORD
(e.g., revascularization procedures) were
considered (Supplementary Table 3).
Exploratory analyses among nonwhite
participants showed significant asso-
ciation of the GRS with MCE among
469 participants of Asian origin but not
among self-reported African American
or Hispanic participants (Supplementary
Table 4).
Replication in the ORIGIN Study
The analysis of 1,931 participants in the
ORIGIN trial, 163 of whom had one or
more MCE during follow-up, confirmed
the results in ACCORD. Each SD incre-
ment in GRS was associated with a 35%
increase in MCE risk (95% CI 16–58),
which was similar to the 27% increase
in risk seen in ACCORD (P for difference
between the two HRs = 0.5). Participants
with a GRS in the third tertile of the
distribution had 90% higher risk of ex-
periencing an MCE event as compared
with those having a GRS in the lowest
tertile (HR 1.90, 95% CI 1.27–2.83), as
shown in Table 2. Adjustment for clinical
predictors modestly attenuated this as-
sociation. Similar results were obtained
Table 1—Characteristics of self-reported white participants with genetic data available included in the ACCORD trial
Characteristic All participants
GRS tertile
Low risk Intermediate risk High risk P
N 5,360 1,787 1,786 1,787
Age (years) 62.8 6 6.5 63.2 6 6.4 62.8 6 6.5 62.3 6 6.5 0.0003
Female 1,888 (35.2) 626 (35.0) 636 (35.6) 626 (35.0) 0.9
Ever smoker 3,348 (62.5) 1,097 (61.4) 1,138 (63.7) 1,113 (62.3) 0.3
BMI (kg/m2) 33.0 6 5.2 33.1 6 5.1 32.9 6 5.2 32.9 6 5.2 0.5
Duration of diabetes (years) 10.7 6 7.5 10.7 6 7.4 10.9 6 7.6 10.5 6 7.3 0.3
Baseline HbA1c (%) 8.2 6 1.0 8.24 6 0.95 8.19 6 0.96 8.21 6 0.95 0.4
Fasting plasma glucose (mg/dL) 178.5 6 50.9 179.2 6 52.0 178.3 6 49.8 178.0 6 50.9 0.8
HDL cholesterol (mg/dL) 40.3 6 10.3 40.7 6 10.4 40.5 6 10.5 39.6 6 9.9 0.005
Total cholesterol (mg/dL) 183.0 6 40.0 182.8 6 39.5 182.3 6 40.1 183.9 6 40.4 0.5
LDL cholesterol (mg/dL) 102.9 6 32.3 102.4 6 31.9 102.2 6 32.2 104.2 6 32.7 0.11
Triglycerides (mg/dL) 203.7 6 122.3 203.2 6 120.6 201.5 6 121.0 206.4 6 125.2 0.5
Statin treatment 3,425 (64.1) 1,070 (60.0) 1,147 (64.4) 1,208 (67.9) ,0.0001
Systolic BP (mmHg) 135.2 6 16.5 135.4 6 16.6 135.0 6 16.4 135.2 6 16.5 0.8
Diastolic BP (mmHg) 74.1 6 10.2 74.3 6 10.3 74.0 6 10.2 74.0 6 10.2 0.6
BP medication 4,419 (82.4) 1,454 (81.4) 1,477 (82.7) 1,488 (83.3) 0.3
Creatinine (mg/dL) 0.90 6 0.22 0.91 6 0.22 0.91 6 0.22 0.90 6 0.22 0.3
Glomerular filtration rate (mL/min/1.7 m2) 88.1 6 21.6 87.4 6 21.1 87.8 6 21.6 89.2 6 22.1 0.04
Family history of CVD 2,629 (50.6) 826 (47.8) 858 (49.5) 945 (54.7) 0.0001
History of CAD 1,643 (30.7) 429 (24.0) 531 (29.7) 683 (38.2) ,0.0001
Rescaled weighted GRS 187.4 6 8.1 178.6 6 4.1 187.4 6 2.0 196.3 6 4.4 N/A
Standardized GRS 0.0 6 1.0 –1.1 6 0.5 0.0 6 0.2 1.1 6 0.5 N/A
Data are mean 6 SD or n (%) unless otherwise noted. To convert the values for glucose to millimoles per liter, multiply by 0.05551. To
convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter,
multiply by 0.01129. To convert the values for creatinine to micromoles per liter, multiply by 88.4. P values for comparison across tertiles
were calculated based on ANOVA or x2 test. BP, blood pressure; CVD, cardiovascular disease; N/A, not applicable.
with an expanded outcome including
coronary revascularization procedures
(276 total events) (Supplementary Table 5).
GRS 3 Environment Interactions
No significant differences were found in
the effect of the GRS when the ACCORD
study population was stratified according
to age, sex, family history of cardiovas-
cular disease, history of CAD, or dura-
tion of diabetes (Supplementary Fig. 2).
A nominally significant larger effect of
the GRS was observed among partici-
pants with baseline HbA1c levels above
the median as compared with those with
values below the median (P for interac-
tion = 0.02). Such difference was not
observed when participants were strat-
ified based on their average on-trial
HbA1c levels (Supplementary Table 6).
Similarly, none of the ACCORD random-
ized interventions (i.e., intensive vs.
standard glycemic control, fenofibrate +
simvastatin vs. placebo + simvastatin,
and intensive vs. standard blood pressure
control) showed a significant interaction
with the GRS on MCE (all P for interac-
tion . 0.1). The same analyses, illus-
trated from a different perspective in
Supplementary Fig. 3, showed that the
treatments compared in the trial had
similar effects on MCE across GRS ter-
tiles. A sensitivity analysis excluding
219 participants with follow-up (time
to event or to censoring) #1 year, in
order to allow for sufficient time for the
intervention to be modified by genetic
background, provided similar results
(all P for interaction . 0.4).
MCE Prediction Model Performance,
Discrimination, and Calibration
The AUC for a genetic prediction model
of incident MCE including the GRS alone
was 0.57 as compared with 0.67 for a
clinical prediction model including his-
tory of CAD, 10-year ASCVD risk score,
age, sex, and other ACCORD study co-
variates. Addition of GRS to the clinical
model marginally improved the AUC
(AUC difference +0.007, P = 0.04) (Fig.
2A). Despite the minimal increase in AUC,
the clinical + genetic prediction model
showed a substantial increase in the rIDI
(rIDI +8%, P = 0.0007) along with an NRI of
0.16 (P , 0.0001), with 8% of events and
9% of nonevents correctly reclassified
by the new model. Goodness-of-fit test
(Hosmer and Lemeshow) showed ade-







































































































































































































































































































































































































































































































































































































































































































































































































































































clinical + genetic models (P = 0.4 and P =
0.2, respectively). Results were similar
if the GRS was added to an expanded
clinical prediction model that also in-
cluded HbA1c levels, duration of diabetes,
and family history of cardiovascular dis-
ease (AUC increase 0.007, P = 0.03; rIDI
+7%, P = 0.002; NRI +13%, P = 0.002).
Comparison of the Performances of
Different GRSWith Increasing Number
of CAD Loci
Finally, we tested whether the inclusion
of the newly identified CAD loci and
variants available in December 2017
and included in the 204-SNP–based
GRS (representing 160 CAD loci) im-
proved incident MCE prediction as com-
pared with the GRS based on the smaller
number of CAD variants available in
2010 (13-SNP–based GRS, representing
12 CAD loci), 2011 (30-SNP–based GRS,
representing 29 CAD loci), 2013 (53-SNP–
based GRS, representing 45 CAD loci),
or 2015 (70-SNP–based GRS, repre-
senting 57 CAD loci). The variants in-
cluded in each of these GRS are listed
in Supplementary Table 1. As shown in
Fig. 2B, the increasing number of CAD
loci and variants from 2010 to 2017 was
paralleled by an increasingly stronger
association between GRS and MCE.
Whereas the 12-CAD-loci GRS from
2010 was associated with a 9% increase
(95% CI 1–17) in the odds of MCE per
SD, the corresponding value for the
160-CAD-loci GRS from 2017 was 27%
(95% CI 18–37) (P for differences be-
tween HRs = 0.002). Consistent with this,
there was a linear improvement from
2010 to 2017 in the GRS discrimination
of participants experiencing MCE from
those with no events during follow-up
(Fig. 2C and Supplementary Fig. 4). How-
ever, when the improvement in discrim-
ination was plotted against the number
of CAD loci included in each GRS (Fig.
2D), a tendency toward a plateau in this
relationship was observed, indicating that
the improvement in discrimination ob-
served during the past 2 years required
the addition of a much larger number of
new CAD loci than in previous years.
CONCLUSIONS
Our understanding of the genetic archi-
tecture of CAD has been constantly im-
proving during the past decade in parallel
with the identification of an increasing
number of genetic loci associated with
this multifactorial disease. In the general
population, the number of genetic loci
harboring common variants (i.e., having
minor allele frequency $1%) that are
robustly associated with CAD has in-
creased from 12 in 2010 to 160 in
2017 (8–18). In this study, we found
that a GRS capturing the information
provided by all the CAD loci identified
to date in the general population was
strongly associated with the prevalence
and incidence of CAD also among sub-
jects with type 2 diabetes. This associa-
tion was independent of classical clinical
cardiovascular risk factors, family his-
tory of cardiovascular disease, previous
history of CAD, and duration of diabetes
and did not influence the effectiveness
of interventions aimed at decreasing
cardiovascular morbidity such as inten-
sive glycemic and blood pressure con-
trol and lipid-lowering treatment with
fenofibrate. Interestingly, while clini-
cal risk factors clearly outperformed
the GRS as predictors of incident MCE,
addition of the GRS to a clinical prediction
model provided a modest but significant
improvement in the discrimination of
participants who developed events
from those who did not. Such improve-
ment depended on the number of loci
captured by the GRS, with the most
updated list of CAD loci clearly outper-
forming GRS based on the smaller num-
ber of CAD loci available in previous
years.
These results have several important
implications. First, they confirm the over-
all transferability of CAD loci from the
general to the population with type 2
diabetes. Few studies have previously
investigated this concept. In 2011, Qi
et al. (19) reported that a GRS based
on five CAD loci from the general pop-
ulation was significantly associated with
prevalent or incident CAD among sub-
jects with type 2 diabetes. Similarly, in
the Diabetes Heart Study, a GRS based on
28 CAD loci was associated with history of
cardiovascular disease and with levels of
coronary artery calcification (31). More
recently, a GRS based on 153 SNPs as-
sociated with CAD at genome-wide sig-
nificant levels or surviving a 5% false
discovery rate in the general population
(8) was found tobe significantly associated
with incident cardiovascular events (in-
cluding stroke) in the Look AHEAD trial
(32). Taken together, these findings
from the ACCORD and ORIGIN stud-
ies indicate that the genetic loci that
influence CAD risk in the general popu-
lation generally do so also in the pres-
ence of diabetes. In other words, the
high cardiovascular risk conferred by the
exposure to the diabetic milieu does
not appear to override the genetic fac-
tors influencing CAD risk in the general
population. Thus, any future therapeu-
tic advancements that may stem from
the study of the mechanistic links be-
tween these160 loci andatherosclerosis
are likely to also benefit patients with
type 2 diabetes. This is in addition to the
benefits that may arise from the study
of CAD loci that are specific to type 2
diabetes such as GLUL (20).
Figure 1—Kaplan-Meier curves for MCE according to genetic risk category.
Figure 2—A: ROC curves for the predictive performance of MCE using GRS (green), clinical predictors (blue), or the combination of them (red) in the
ACCORD trial (5,322 subjects included in the analysis; 667 events). Clinical predictors include history of CAD, ASCVD risk score, age, sex, and ACCORD
study covariates. B: Association with MCE of different GRS based on the increasing number of CAD SNPs. GRS are ordered from top to bottom in
chronological order (years are reported in brackets), with an increasing number of CAD loci for each GRS. C and D: Improvement in discrimination
for MCE with GRS from 2010 to 2017 (plotted against year of discovery in C and against the number of CAD loci included in each GRS in D). The y-axis
shows the percent increase in rIDI when each GRS was added to the model including clinical predictors.
Second, our findings indicate that the
information provided by the CAD loci
included in the GRS can be used to im-
prove the identification of individuals
with diabetes at high risk of MCE events.
While this improvement may appear
modest (+0.01 increase in AUC, 8% in-
crease in rIDI, and 8% of events and 9%
of nonevents correctly reclassified by the
continuous NRI), it is substantial in the
context of the thresholds commonly used
to add new biomarkers to established
prediction tools (33,34). For instance,
during the development of the widely
used ACC/AHA pooled cohort equations
to assess ASCVD risk (6), new biomarkers
were deemed to beworth their addition
to the equation based on an rIDI im-
provement of 6% or moreda criterion
that would have been met by the GRS
described in the current study. It is also
interesting to note that, as observed in the
general population (35–37), the improve-
ment in risk discrimination provided by
the GRS has been increasing over the
years with the addition of new CAD loci,
despite the increasingly smaller effects of
the newly identified loci.We can therefore
reasonably expect further prediction im-
provements deriving from the identifi-
cation of additional CAD loci through the
larger studies that are currently underway
(38). While our data suggest that the
improvement in discrimination provided
by each newly discovered locus is pro-
gressively declining, the greater power of
the current studies may compensate for
this by increasing the rate of discovery of
new CAD loci. Better prediction models
will help maximize cost-effectiveness,
by directing preventive interventions to
high-risk subjects, and may also enhance
the power of clinical trials, by allowing
the selection of individuals with a high
likelihood to experience an event dur-
ing the study (39). At the clinical level,
disclosure and discussion of information
about genetic risk with patients could
lead to better shared decisions on treat-
ment and higher adherence to them
(40).
While the GRS described in this article
may help identify patients at high risk of
MCE, it does not seem to be useful for
personalizing their treatment, at least
with regard to the interventions inves-
tigated in ACCORD. In this subcohort
of the trial (including only white par-
ticipants who provided genetic consent,
i.e., ;80% of all self-reported white
participants), intensive glycemic con-
trol and fenofibrate treatment were
associated with 15% and 19% reductions
inMCE risk, respectively (HR 0.85, 95% CI
0.73–0.97, P = 0.04, and HR 0.82, 95% CI
0.67–1.00, P = 0.05). These effects were
similar across GRS classes, suggesting
that the genetic heterogeneity captured
by the CAD-GRS does not generally over-
lap with the heterogeneity observed in
the response to these treatments. Con-
sistent with this tenet is the fact that the
two loci influencing the cardiovascular
response to intensive glycemic control
in ACCORD that were recently identified
by our group (27) are not among the
160 CAD loci discovered to date. None-
theless, this does not exclude the pos-
sibility that variants at some of these
loci, in particular those involved in the
pathways directly targeted by treat-
ments, may individually influence treat-
ment outcomes. An example of this is the
common gain-of-function mutation in the
LPL gene coding for lipoprotein lipase (an
established CAD locus), which we have
recently found to influence the cardio-
vascular response to fenofibrate (28), a
PPAR-a agonist with known effects on
LPL expression and lipoprotein lipase
activity (41).
This study, conducted in the rigorous
clinical trial setting of ACCORD and
ORIGIN, with precise definitions and classi-
fications of CAD and MCE, is one of the
largest efforts to examine the association
between a GRS derived from the general
population and coronary events in pa-
tientswith type 2 diabetes. However, the
results of this study should be considered
in the context of its potential limitations.
One concerns the exclusive focus on non-
Hispanic whites and on genetic loci dis-
covered in this ethnic group due to the
relatively small number of nonwhites in
ACCORD. As the genetic architecture
of CAD and linkage disequilibrium pat-
terns may differ across races, one cannot
extrapolate these findings to other racial
or ethnic groups. A second limitation con-
cerns the possibility of a false negative
result regarding the GRS 3 treatment
interaction due to the fact that gene 3
treatment interactions on CAD outcomes
may be easier to detect in primary pre-
vention studies, as suggested by previ-
ous reports concerning statins (42,43).
Since more than one-third of ACCORD
participants were in secondary prevention
and all others had multiple cardiovascular
risk factors, one cannot exclude an in-
fluence of the GRS on treatment re-
sponses among subjects with lower
cardiovascular risk. For these reasons,
our results appear to be generalizable to
self-reported white subjects with type 2
diabetes at high cardiovascular risk, as
confirmed also by the replication of
these findings in the ORIGIN study.
Finally, despite the relatively large sam-
ple size, we had limited power to ana-
lyze the effects of individual SNPs. Thus,
even if the association of the GRS with
CAD and MCE was highly significant, we
could draw limited conclusions about
the transferability of individual CAD
loci from the general population to
type 2 diabetes.
Conclusion
In conclusion, a GRS combining informa-
tion from the 160 CAD loci identified in
the general population as of December
2017 was strongly associated with CAD
history and MCE incidence in participants
with type 2 diabetes from the ACCORD
and ORIGIN studies. This GRS provided a
significant improvement in the perfor-
mance of a prediction model based on
clinical risk factors. Given the trend in
GRS performance observed from 2010 to
2017 as well as the exponential increase
in the size of genetic studies, we can
reasonably expect that the discovery of
additional CAD loci in coming years will
further improve our ability to identify
patients with type 2 diabetes at espe-
cially high cardiovascular risk and will
provide novel insights into the genetic
heterogeneity of CAD among subjects
with and without diabetes.
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